Chief Executive Officer, BioArctic
Appears in 1 story
Original developer of the antibody; receives royalties on IQLIK sales
Since 2023 the Alzheimer's drug Leqembi came with a catch: patients needed intravenous infusions at a clinic every two weeks for 18 months. On August 24, Eisai and Biogen removed that hurdle, making a subcutaneous autoinjector version, LEQEMBI IQLIK, available from the very first dose.
Updated Aug 25
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
